Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Wysocki P, Jung K, Oh D, Doroshow D, Artamonova E, Mammatas L, SU P, Moiseyenko V, Penkov K, Stroyakovskiy D, Bartolome J, Siena S, Fielding A, Jung L, Michelini F, Puvvada S, Makker V. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. Journal Of Clinical Oncology 2024, 42: 4565-4565. DOI: 10.1200/jco.2024.42.16_suppl.4565.Peer-Reviewed Original ResearchDisease control rateProgression-free survivalDuration of responseT-DXdPretreated ptsHER2 expressionUrothelial cancerBladder cohortEfficacy outcomesSolid tumorsSafety of trastuzumab deruxtecanDrug-related adverse eventsPhase 2 studyClinically meaningful responseGrade (GHER2 expression levelsTrastuzumab deruxtecanAdvanced/metastatic diseaseData cutoffPD-L1Open-labelExploratory endpointsPrimary endpointSystemic treatmentSecondary endpoints